- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 9 listed it in both
- Shares listed
- 167,083,807
- combined, among listed positions
- Reported value
- $9.2bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 9 buyers (opened or added shares) and 19 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -15,023,946.
Managers listing GSK in Q1 2026
20 of 20 holders
Largest increases and reductions, by shares
Increases
- Acadian Asset Management LLCexisting position · 11,797,085 shares now+2,832,926
- Walleye Capital LLCexisting position · 373,096 shares now+321,192
- MFS Investment Managementnew position · 212,366 shares now+212,366
- Fidelity (FMR LLC)existing position · 67,661,646 shares now+192,237
- Susquehanna International Group LLPexisting position · 57,448 shares now+48,853
Reductions
- Dodge & Coxexisting position · 58,662,974 shares now-9,854,995
- Holocene Advisors LPexisting position · 5,518,433 shares now-2,598,094
- Wellington Management Group LLPexisting position · 11,717,613 shares now-839,874
- Renaissance Technologies LLCexisting position · 311,292 shares now-724,280
- Bridgewater Associates LPexisting position · 698,666 shares now-717,859
New positions and exits
New (3)
- MFS Investment Management$12m
- Invesco Ltd$259k
- AllianceBernstein LP$208k
Exited (8)
- Point72 Asset Management LPwas $72m
- Marshall Wace LLPwas $19m
- Citadel Advisors LLCwas $10m
- Schonfeld Strategic Advisors LLCwas $5.3m
- Quantbot Technologies LPwas $1.9m
- Two Sigma Investments LPwas $1.8m
- Balyasny Asset Management LLCwas $783k
- D. E. Shaw & Co.was $272k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →